Quick Answer
Monte Rosa Therapeutics, Inc. reported Total Assets of $448.66 million for fiscal year 2025.
Monte Rosa Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $448.66M | +2.3% |
| 2024 | $438.73M | +44.4% |
| 2023 | $303.75M | -11.3% |
| 2022 | $342.39M | -6.5% |
| 2021 | $366.33M | +641.9% |
| 2020 | $49.38M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $459.84M | +45.9% | +27.9% |
| June 30, 2025 | $359.59M | +4.5% | -8.5% |
| March 31, 2025 | $393.20M | +47.4% | -10.4% |
| December 31, 2024 | $438.73M | +44.4% | +39.2% |
| September 30, 2024 | $315.08M | +25.0% | -8.4% |
| June 30, 2024 | $344.11M | +23.5% | +29.0% |
| March 31, 2024 | $266.75M | -13.7% | -12.2% |
| December 31, 2023 | $303.75M | -11.3% | +20.5% |
- Monte Rosa Therapeutics, Inc. showed an increase of +2.3% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Monte Rosa Therapeutics, Inc.’s total assets has grown by 808.6% (from $49.38 million to $448.66 million).
- The most recent figure is from Monte Rosa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: